WuXi XDC Cayman, Inc. (2268) AI Stock Analysis

• Market Cap: HK$70.95B
• Dividend Yield: N/A
• Average Volume (3M): 6.04M
• Price to Earnings (P/E): 60.6
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 2,041
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.54
• Shares Outstanding: 1,204,524,800
• 10 Day Avg. Volume: 8,248,219
• 30 Day Avg. Volume: 6,039,476
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$56.55
• Price Target Upside: -1.48% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: HK$58.00 ▲(1.05% Upside)

WuXi XDC Cayman, Inc. has strong financial performance, characterized by robust revenue and profit growth, but faces challenges with negative free cash flow. The stock's technical indicators show bullish momentum, although it is overbought. High valuation metrics limit upside potential, making the stock moderately attractive.

WuXi XDC Cayman, Inc. Business Overview & Revenue Model

Company Description

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

How the Company Makes Money

WuXi XDC Cayman, Inc. generates revenue through a service-based business model, offering end-to-end solutions for the development and production of antibody-drug conjugates. The company's key revenue streams include fees from research and development services, manufacturing services, and licensing agreements. By collaborating with pharmaceutical and biotechnology companies, WuXi XDC assists in bringing novel therapies to market, earning revenue from both upfront payments and milestone payments associated with successful project advancement. Additionally, strategic partnerships and alliances within the biopharmaceutical industry play a significant role in expanding the company's reach and enhancing its service offerings.

WuXi XDC Cayman, Inc. Financial Statement Overview

Summary

WuXi XDC Cayman, Inc. shows strong revenue and profit growth with a robust equity position. However, significant capital expenditures have resulted in negative free cash flow, which may pose liquidity risks if not addressed.

Income Statement

WuXi XDC Cayman, Inc. has demonstrated impressive revenue growth, with a 90.8% increase from 2023 to 2024 and a substantial gross profit margin of 30.6% in 2024. The net profit margin stands at a robust 26.4%, indicating strong profitability. EBIT and EBITDA margins are also strong at 23.4% and 32.9%, respectively, underscoring efficient operations.

Balance Sheet

The company has a solid equity position with a debt-to-equity ratio of 0.07, indicating low leverage. The return on equity is strong at 16.1%, reflecting effective use of shareholder funds. An equity ratio of 72.8% suggests a stable financial foundation with a substantial portion of assets funded by equity.

Cash Flow

Operating cash flow has increased, yet the free cash flow remains negative at -$787.95 million due to significant capital expenditures. However, the operating cash flow to net income ratio of 0.67 reflects reasonable cash conversion from earnings, while the free cash flow to net income ratio is negative, indicating pressure on cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.05B	2.12B	990.42M	311.13M	96.35M
Gross Profit	1.24B	559.56M	261.08M	113.49M	8.08M
EBITDA	1.33B	420.28M	272.90M	96.89M	46.12M
Net Income	1.07B	283.54M	155.73M	54.93M	26.30M
Balance Sheet
Total Assets	9.12B	6.74B	2.50B	879.75M	408.47M
Cash, Cash Equivalents and Short-Term Investments	3.97B	4.05B	734.97M	26.32M	28.39M
Total Debt	496.43M	2.84M	77.18M	24.59M	0.00
Total Liabilities	2.48B	1.28B	1.02B	858.87M	32.79M
Stockholders Equity	6.64B	5.45B	1.48B	20.88M	375.68M
Cash Flow
Free Cash Flow	-787.95M	-206.51M	-135.74M	7.23M	-32.03M
Operating Cash Flow	717.22M	332.85M	251.82M	59.14M	20.85M
Investing Cash Flow	-3.33B	-91.23M	-1.28B	-51.59M	-52.42M
Financing Cash Flow	475.36M	3.52B	1.33B	22.34M	69.12M

WuXi XDC Cayman, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 57.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Positive. The current price of 57.4 is above the 20-day moving average (MA) of 54.18, above the 50-day MA of 46.86, and above the 200-day MA of 35.63, indicating a bullish trend. The MACD of 3.72 indicates Positive momentum. The RSI at 62.36 is Neutral, neither overbought nor oversold. The STOCH value of 46.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2268.

WuXi XDC Cayman, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	67 Neutral	HK$70.95B	60.56	17.75%	―	―	―
Sector *	56 Neutral	$6.41B	9.61	-29.56%	6.32%	10.97%	-32.97%
5HZ1	―	€6.28B	123.20	1.58%	―	―	―
2359	83 Outperform	HK$286.61B	20.38	23.23%	0.38%	6.94%	42.86%
6127	56 Neutral	HK$24.31B	43.64	4.83%	0.15%	-15.92%	―

WuXi XDC Cayman, Inc. Corporate Events

WuXi XDC Cayman Inc. Announces Significant Profit Growth for H1 2025

WuXi XDC Cayman Inc. has announced a positive profit alert, projecting significant financial growth for the first half of 2025. The company expects over a 60% increase in revenue, more than a 67% rise in adjusted net profit before interest income and expense, and over a 50% increase in net profit compared to the same period in 2024. This growth is attributed to the sustained demand in the ADC and bioconjugate industry, the company’s market leadership, and improved operational efficiencies. These results highlight WuXi XDC’s strong industry positioning and potential for long-term sustainability and value creation.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman Inc. Schedules Board Meeting for Interim Results Review

WuXi XDC Cayman Inc. has announced a board meeting scheduled for August 18, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.

The most recent analyst rating on (HK:2268) stock is a Buy with a HK$60.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Announces AGM Results and Board Changes

WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, held its annual general meeting on June 27, 2025, where all proposed resolutions were passed by shareholders. Key changes include the retirement of Dr. Weichang Zhou and the appointment of Dr. Jijie Gu as a non-executive director, along with updates to the composition of various board committees.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman Inc. Announces Board Composition and Committee Roles

WuXi XDC Cayman Inc. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. The board is structured to oversee various committees, such as audit, remuneration, nomination, strategy, and environmental, social, and governance, ensuring comprehensive governance and strategic oversight. This announcement highlights the company’s commitment to robust corporate governance, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman Inc. Reschedules 2024 AGM Date

WuXi XDC Cayman Inc., a company incorporated in the Cayman Islands, has announced a change in the date of its 2024 annual general meeting (AGM). Originally scheduled for June 25, 2025, the AGM will now take place on June 27, 2025, due to administrative reasons. Consequently, the book closure period for determining shareholders’ eligibility to attend and vote has been adjusted to June 24-27, 2025.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

WuXi XDC Cayman Inc. Announces Annual General Meeting and Strategic Resolutions

WuXi XDC Cayman Inc. has announced its Annual General Meeting scheduled for June 27, 2025, in Wuxi City, China. The meeting will address several key agenda items, including the reception of audited financial statements, re-election and appointment of directors, and authorization of directors’ remuneration. Additionally, the company seeks approval for a mandate to issue and allot shares, reflecting its strategic focus on expanding its operational capabilities and enhancing shareholder value.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.